Osteoporosis disease is the most prevalent disease that occurs due to bone mineral density which causes heavy risk of fractures and bone fragility. The disease occurs mostly in spine, hip, shoulder and forearm.Hip fractures are most common as nearly one-third of patients lose mobility and need long-term nursing. As patients are unable to move, prolonged complications arising out of bed immobilization ultimately results into fatality. The diagnostic measures of osteoporosis include X-ray and radiography tests that are further acknowledged with bone density test.
Osteoporosis is more prevalent in geriatric women than men; hence the suggested treatment is known as anti-osteoporosis which is intended to increase the bone mineral density and keeps a control over loss of bone tissue. Anti-osteoporosis reduces the risk of fractures by significant percent.
The medicines used against osteoporosis mainly contain bisphosphonate molecules. The anti-osteoporosis market and fracture healing market is thus projected to register a healthy CAGR during the forecast period. The driving factors responsible for the growth of anti-osteoporosis therapy and fracture healing market include increasing prevalence of osteoporosis in aged women, rise in incidence of osteoporosis patients andgrowing prevalence of bone diseases resulting out of changing lifestyle are some factors fueling the market growth.Additionally, growth in investments in R&D for generation of drugs and increasing awareness about osteoporosis are also adding to the growth of osteoporosis market.
However, factors like complications and side effects obtained from these therapies such as nausea, irritable bowel syndrome, symptoms of influenza,stomach ulcers and esophagus. Overall, the global anti-osteoporosis therapy and fracture healing market is projected to grow at a higher CAGR owing to efficiency of driving factors and increasing benefits of anti-osteoporosis therapies over other osteoporosis therapies. On the basis of administration, the global anti-osteoporosis therapy market includes oral and injectable.
On the drug type, the global anti-osteoporosis therapy market includes biophosphonates, alendronate, risedronate, ibandronate, zoledronic acid, selective oestrogen receptor modulators (SERM). SERM is further sub-segmented into raloxifene and strontium ranelete. On the basis of geographic segmentation, the global anti-osteoporosis therapy market spans North America, Europe, Asia-Pacific, Middle-East and Africa.
North America leads the global anti-osteoporosis global market owing to rise in investment in R&D for generation of new drugs, growing geriatric population and increasing incidence of diseases yielding out of modified lifestyle. APAC regions exhibit a higher growth rate during the forecast period. Regions like India and China are projected to be the fastest growing market for anti-osteoporosis therapy and fracture healing market. The key players in the global anti-osteoporosis market include Eli Lilly and Company, Actavis plc, Teva Pharmaceutical Industries Ltd., Merck and Company Inc., F.Hoffmann La Roche Ltd., Amgen Inc., Pfizer, Inc., Novartis International AG., and GlaxoSmithKline plc.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.